December 17, 2014

Integra LifeSciences Launches Integra(R) Meshed Dermal Regeneration Template

Expands Skin and Wound Product Line

PLAINSBORO, N.J., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of Integra® Meshed Dermal Regeneration Template. Integra Meshed Dermal Regeneration Template has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA), and expects to begin a full market release in the United States in January 2015. Integra's newest skin product will be featured at the John A. Boswick Burn and Wound Care Symposium, February 14-18, 2015.

"Integra Meshed Dermal Regeneration Template is currently the only pre-meshed bilayer matrix approved by the FDA for third-degree burns and scar contracture procedures," said William Weber, Vice President and General Manager, Integra Orthopedics and Tissue Technologies. "It complements our burn product portfolio, and combines the proven collagen technology of Integra Dermal Regeneration Template with the convenience of a pre-meshed configuration."

Integra Meshed Dermal Regeneration Template is a collagen-chondroitin-6-sulfate, pre-meshed bilayer matrix indicated for the postexcisional treatment of life-threatening full-thickness or deep partial-thickness thermal injuries, and the repair of scar contractures when other therapies have failed. Terminally sterilized, Integra Meshed Dermal Regeneration Template is conveniently stored at room temperature, has a 24-month shelf life, and is intended for one-time use.

Integra offers a versatile range of skin repair solutions to meet the surgeon's procedural needs, including Integra® Dermal Regeneration Template, one of the first regenerative medicine products approved by the FDA; Integra® Meshed Bilayer Wound Matrix, which can be used with Negative Pressure Wound Therapy; and Integra® Flowable Wound Matrix, designed for easy application to tunneled and/or undermined wounds. Together, these products represent over 30 years of science and innovation in the development of collagen technology. Integra's Ultra Pure Collagen™ is the base material of implants used successfully in over 12 million procedures.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences:

Media

Gianna Sabella

609-936-2389

gianna.sabella@integralife.com

Investors

Angela Steinway

609-936-2268

angela.steinway@integralife.com